Trials / Unknown
UnknownNCT03083119
Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina
The Methylation Regulation Mechanism of Blood Stasis Relevant miRNA Expression on Coronary Heart Disease
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Jie Wang · Academic / Other
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, typical cases of coronary heart disease are selected. They will be intervened by Xuesaitong soft capsules to investigate efficacy and safety for Coronary Heart disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xuesaitong soft capsule | Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month. |
| DRUG | Placebo oral capsule | Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month. |
Timeline
- Start date
- 2017-03-20
- Primary completion
- 2017-04-20
- Completion
- 2017-08-20
- First posted
- 2017-03-17
- Last updated
- 2017-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03083119. Inclusion in this directory is not an endorsement.